Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00140504 · ClinicalTrials.gov registry record · NA
Preventing Adverse Drug Events With PatientSite
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 800
- Enrollment target
NCT00140504 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 800 participants.
The verdict
NCT00140504, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 800 participants
- Enrollment target
Study Summary
This is a study to better understand the nature and extent of adverse drug events (ADEs), defined as injuries due to prescription medications, in primary care. We will study whether PatientSite (an internet-based communication program for patients and health care providers) can improve clinicians' ability to detect adverse drug events among primary care patients and to mitigate the consequences by sending electronic queries to patients after they receive new medication prescriptions.
Interventions
- OTHER Medcheck message
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2003-04 |
| Est. Completion | 2004-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00140504
The ClinicalTrials.gov registry entry for NCT00140504 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Medcheck message is the first listed.
NCT00140504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00140504 about?
NCT00140504 is a clinical study titled "Preventing Adverse Drug Events With PatientSite". This is a study to better understand the nature and extent of adverse drug events (ADEs), defined as injuries due to prescription medications, in primary care. We will study whether PatientSite (an internet-based communication program for patients and health care providers) can improve clinicians' a...
What is the current status of trial NCT00140504?
This trial is currently completed. It is a NA study. The enrollment target is 800 participants. The study started on 2003-04. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00140504?
The interventions under investigation include: Medcheck message (OTHER).
Who is sponsoring clinical trial NCT00140504?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.